Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-01-02 Sale | 2025-01-03 4:15 pm | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Financial Officer | 6,954 | $0.9837 | $6,841 | 321,546 (Direct) | View |
| 2025-01-02 Sale | 2025-01-03 4:15 pm | Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 1,803 | $0.9837 | $1,774 | 78,197 (Direct) | View |
| 2024-12-18 Purchase | 2024-12-19 4:19 pm | Xilio Therapeutics Inc. | XLO | GILEAD SCIENCES INC. 10% Owner | 1,759,978 | $1.04 | $1,830,377 | 19,080,717 (Direct) | View |
| 2024-04-02 Purchase | 2024-04-03 6:50 pm | Xilio Therapeutics Inc. | XLO | GILEAD SCIENCES INC. 10% Owner | 485,250 | $0.76 | $368,790 | 11,227,923 (Direct) | View |
| 2024-02-08 Sale | 2024-02-09 4:33 pm | Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC 10% Owner | 1,000 | $0.64 | $640 | 2,754,109 (Indirect Direct) | View |
| 2024-01-11 Sale | 2024-01-16 6:16 pm | Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC 10% Owner | 4,235 | $0.85017 | $3,600 | 2,755,109 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-06-11 Option Award | 2025-06-12 4:37 pm | N/A 2035-06-10 | Xilio Therapeutics Inc. | XLO | ROSS ROBERT W. Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 4:37 pm | N/A 2035-06-10 | Xilio Therapeutics Inc. | XLO | Brennan Aoife Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 4:36 pm | N/A 2035-06-10 | Xilio Therapeutics Inc. | XLO | Bonstein Sara Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 4:36 pm | N/A 2035-06-10 | Xilio Therapeutics Inc. | XLO | Curran Daniel J. Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 4:36 pm | N/A 2035-06-10 | Xilio Therapeutics Inc. | XLO | Clancy Paul J Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 4:35 pm | N/A 2035-06-10 | Xilio Therapeutics Inc. | XLO | Xu Yuan Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 4:35 pm | N/A 2035-06-10 | Xilio Therapeutics Inc. | XLO | Shannon James Samuel Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 4:34 pm | N/A 2035-06-10 | Xilio Therapeutics Inc. | XLO | Rossi Christina Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2025-06-10 Option Award | 2025-06-12 4:34 pm | N/A 2035-06-09 | Xilio Therapeutics Inc. | XLO | Bello Akintunde Olatokumbo Director | 62,000 | $0 | 62,000 (Direct) | View |
| 2025-04-15 Option Award | 2025-04-16 4:30 pm | N/A 2035-04-14 | Xilio Therapeutics Inc. | XLO | Russo Rene PRESIDENT AND CEO | 190,000 | $0 | 190,000 (Direct) | View |
| 2025-04-15 Option Award | 2025-04-16 4:30 pm | N/A 2035-04-14 | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Financial Officer | 75,000 | $0 | 75,000 (Direct) | View |
| 2025-01-01 Exercise | 2025-01-03 4:15 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Luptakova Katarina CHIEF MEDICAL OFFICER | 16,625 | $0 | 266,500 (Direct) | View |
| 2025-01-01 Option Award | 2025-01-03 4:15 pm | N/A 2035-12-31 | Xilio Therapeutics Inc. | XLO | Luptakova Katarina CHIEF MEDICAL OFFICER | 200,000 | $0 | 266,500 (Direct) | View |
| 2025-01-01 Exercise | 2025-01-03 4:15 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Financial Officer | 19,375 | $0 | 321,546 (Direct) | View |
| 2025-01-01 Option Award | 2025-01-03 4:15 pm | N/A 2035-12-31 | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Financial Officer | 251,000 | $0 | 321,546 (Direct) | View |
| 2025-01-01 Exercise | 2025-01-03 4:15 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 5,000 | $0 | 78,197 (Direct) | View |
| 2025-01-01 Option Award | 2025-01-03 4:15 pm | N/A 2035-12-31 | Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 60,000 | $0 | 78,197 (Direct) | View |
| 2025-01-01 Exercise | 2025-01-03 4:15 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Russo Rene PRESIDENT AND CEO | 44,250 | $0 | 1,015,633 (Direct) | View |
| 2025-01-01 Option Award | 2025-01-03 4:15 pm | N/A 2035-12-31 | Xilio Therapeutics Inc. | XLO | Russo Rene PRESIDENT AND CEO | 638,000 | $0 | 1,015,633 (Direct) | View |
| 2024-10-01 Option Award | 2024-10-02 5:15 pm | N/A 2034-09-30 | Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 26,000 | $0 | 26,000 (Direct) | View |
Ownership | 2024-09-27 9:00 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Chudnovsky Yekaterina GKCC LLC 10% Owner | 0 | $0 | 7,000,000 (Indirect) | View |
| 2024-08-03 Option Award | 2024-08-06 8:00 pm | N/A 2034-08-02 | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Operating Officer | 52,000 | $0 | 52,000 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-17 4:30 pm | N/A 2034-06-13 | Xilio Therapeutics Inc. | XLO | Xu Yuan Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-17 4:30 pm | N/A 2034-06-13 | Xilio Therapeutics Inc. | XLO | Bonstein Sara Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-17 4:30 pm | N/A 2034-06-13 | Xilio Therapeutics Inc. | XLO | ROSS ROBERT W. Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-17 4:30 pm | N/A 2034-06-13 | Xilio Therapeutics Inc. | XLO | Rossi Christina Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-17 4:30 pm | N/A 2034-06-13 | Xilio Therapeutics Inc. | XLO | Clancy Paul J Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-17 4:30 pm | N/A 2034-06-13 | Xilio Therapeutics Inc. | XLO | Curran Daniel J. Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2024-06-13 Option Award | 2024-06-17 4:12 pm | N/A 2034-06-12 | Xilio Therapeutics Inc. | XLO | Shannon James Samuel Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2024-06-13 Option Award | 2024-06-17 4:10 pm | N/A 2034-06-12 | Xilio Therapeutics Inc. | XLO | Brennan Aoife Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 4:10 pm | N/A 2034-04-30 | Xilio Therapeutics Inc. | XLO | Luptakova Katarina CHIEF MEDICAL OFFICER | 59,333 | $0 | 59,333 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 4:10 pm | N/A 2034-04-30 | Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 20,000 | $0 | 20,000 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 4:10 pm | N/A 2034-04-30 | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James CHIEF OPERATING OFFICER | 208,000 | $0 | 208,000 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 4:10 pm | N/A 2034-04-30 | Xilio Therapeutics Inc. | XLO | Russo Rene PRESIDENT AND CEO | 474,000 | $0 | 474,000 (Direct) | View |
Ownership | 2024-04-03 6:48 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | GILEAD SCIENCES INC. 10% Owner | 0 | $0 | 6,860,223 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 4:38 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James CHIEF OPERATING OFFICER | 77,500 | $0 | 77,500 (Direct) | View |